Claims

[Claim 1] A composition for use in treating rare genetic obesity diseases associated with proopiomelanocortin (POMC) deficiency, comprising a therapeutically effective amount of a compound of Formula 1 or a pharmaceutically acceptable salt thereof:

[Formula 1]



In the Formula 1, R1 is C_2-C_5 alkyl.

[Claim 2] The composition of claim 1, characterized in that the compound of the Formula 1 is *N*-((3*S*,5*S*)-1-((3*S*,4*R*)-1-(*tert*-butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-5-(morpholine-4-carbonyl)pyrrolidin-3-yl)-*N*-((1*s*,4*R*)-4-methylcyclohexyl)isobutyramide of the following Formula 2:

[Formula 2]



.

[Claim 3] The composition of claim 1, characterized in that the pharmaceutically acceptable salt is selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, and hydroiodic acid.

[Claim 4] The composition of claim 1, characterized in that it is an oral dosage form.

[Claim 5] The composition of claim 1, formulated as a pharmaceutical composition together with a pharmaceutically acceptable carrier

[Claim 6] Use of a compound of formula 1 or a pharmaceutically acceptable salt thereof for preparation of a medicament for treating rare genetic obesity diseases associated with proopiomelanocortin (POMC) deficiency:

[Formula 1]



In the Formula 1, R1 is C_2-C_5 alkyl.

[Claim 7] The use of claim 6, characterized in that the compound of Formula 1 is *N*-((3*S*,5*S*)-1-((3*S*,4*R*)-1-(*tert*-butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-5-(morpholine-4-carbonyl)pyrrolidin-3-yl)-*N*-((1*s*,4*R*)-4-methylcyclohexyl)isobutyramide of Formula 2:

[Formula 2]



.

[Claim 8] The use of claim 6, characterized in that the pharmaceutically acceptable salt is selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, and hydroiodic acid.

[Claim 9] The use of claim 6, characterized in that the medicament is an oral formulation.

[Claim 10] The use of claim 6, wherein the therapeutically effective amount is provided at a daily dose of between 0.1 mg to about 500 mg of the compound of Formula 1.

[Claim 11] The use of claim 10, wherein the daily dose is between about 0.1 mg to 300 mg.

[Claim 12] The use of claim 10, wherein the therapeutically effective amount is provided as a unit dosage.

[Claim 13] The use of claim 12, wherein the daily dose comprises one or more unit dosages.

[Claim 14] The use of claim 12, wherein the unit dosage is suitable for parenteral administration, e.g., intramuscular administration or intravenous administration.